NEWS
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib treatment, mice showed significant reduction in lung infiltration and fibrosis, improved clinical scores, reduced vascular smooth muscle hypertrophy, and lower right ventricular systolic blood pressure. These results were validated in a second bleomycin lung injury model.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2468Followers
107Following
26KVisitors
Follow